Novartis concludes Regulus Therapeutics acquisition

Novartis has completed its previously announced acquisition of Regulus Therapeutics for $1.7bn, strengthening its renal disease portfolio.

Jun 27, 2025 - 06:00

Novartis concludes Regulus Therapeutics acquisition

Novartis has completed its previously announced acquisition of Regulus Therapeutics for $1.7bn, strengthening its renal disease portfolio.

Read the original article

Tags:

Previous Article

How AI and machine learning are transforming drug discovery

Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

BMS licenses TCR-T immunotherapy therapy from Immatics

BMS licenses TCR-T immunotherapy therapy from Immatics

May 2, 2023

House Democrats unveil new legislation that expands the Inflation Reduction Act

House Democrats unveil new legislation that expands the...

Aug 14, 2023

STAT+: UnitedHealth cyberattack impedes pharmacies’ and hospitals’ ability to process insurance claims

STAT+: UnitedHealth cyberattack impedes pharmacies’ and...

Feb 23, 2024